The Phantom Link Between Weight-Loss Drugs and Suicide
Regulators reviewed the claim. Here's what the actual science — and the FDA label — say about GLP-1s and mental health.
I now have everything I need. Let me write the article.
A scary headline circulated. Here's what the actual science says.
A story from NewsGuard's Reality Check — published May 26, 2026 — digs into what it calls the phantom link between GLP-1 weight-loss drugs and suicide. It's not the first time this claim has gone viral. And it probably won't be the last.
So let's slow down and actually look at what regulators and researchers found — because the story is more complicated, and ultimately more reassuring, than the panic version suggests.
Where the fear came from
The concern started in 2023 when a small number of adverse event reports to the FDA mentioned suicidal thoughts in people taking semaglutide (Wegovy, Ozempic) and liraglutide (Saxenda). Adverse event reporting systems work by collecting voluntary reports — they are not proof that a drug caused anything. They're a signal-detection tool.
The FDA and the European Medicines Agency (EMA) both launched formal reviews. By April 2024, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) concluded its investigation and found no evidence of a causal link between GLP-1 receptor agonists and suicidal thoughts, according to The Pharmaceutical Journal. TCTMD.com reported the same conclusion from the same PRAC meeting.
What the peer-reviewed data actually shows
Researchers have gone beyond the adverse event databases to look at this more rigorously.
A 2024 study in Scientific Reports — Kornelius et al. — specifically examined the risk of depression, anxiety, and suicidal behavior in people with obesity who were on GLP-1 receptor agonist therapy. That's the right comparison group: people with obesity, not the general population, because obesity itself is associated with higher rates of depression and mood disorders.
A 2024 paper in Expert Opinion on Drug Safety — McIntyre et al. — analyzed reports to the FDA's Adverse Event Reporting System (FAERS) on GLP-1 RAs and suicidality. The same team then replicated their analysis using the World Health Organization's global pharmacovigilance database, VigiBase, publishing those findings in the Journal of Affective Disorders in 2025 — McIntyre et al., 2025. Pharmacovigilance studies like these can identify statistical signals, but as the authors note, they cannot establish causation.
A 2026 systematic review in International Clinical Psychopharmacology — Carminati et al. — looked at semaglutide through the lens of psychiatry, reviewing both potential benefits and risks. The field is still watching, but "ongoing surveillance" is a far cry from "proven danger."
Separately, a 2025 VigiBase study in Clinical Nutrition — Nishida et al. — examined psychiatric and psychological adverse effects associated with dulaglutide, semaglutide, and liraglutide. Again: reports, not confirmed causation.
The confounding problem nobody talks about
Here's the part that gets buried in headlines: people who are prescribed GLP-1 drugs are often already living with obesity — and MedlinePlus notes that mental health conditions including depression are themselves risk factors for suicidal ideation. Untangling whether any psychiatric events are connected to the drug, the underlying condition, or life circumstances is genuinely hard.
This is what researchers call confounding by indication — the people taking a drug for a condition also have elevated baseline risk for other outcomes. Seeing adverse events in a population on a drug doesn't mean the drug caused them.
Psychiatry Online published a commentary in August 2025 directly addressing this — framing the debate as "association versus causation" and calling for ongoing surveillance rather than alarm.
What Wegovy's FDA label actually lists
It's worth going to the primary source. According to the FDA's approved label for Wegovy, the listed warnings and precautions cover pancreatitis, gallbladder disease, kidney injury, heart rate increase, and thyroid tumors in rodents — among others. Suicidality is not listed as a labeled warning or precaution. The most common adverse reactions listed are gastrointestinal: nausea, diarrhea, vomiting, constipation, and abdominal pain.
That doesn't mean the question is permanently closed. Labels get updated when evidence warrants it. But as of now, it's not there.
What this means for you
- The EMA completed a formal review and found no causal link between GLP-1 drugs and suicidal thoughts. The FDA's review reached a similar conclusion. That's not a dismissal — it's the result of a real investigation.
- Adverse event reports are signals, not proof. They're the starting point for research, not the ending point for headlines.
- If you're experiencing mood changes, depression, or any thoughts of self-harm while on a GLP-1 medication — or off one — that's a conversation to have with your prescriber immediately. The 988 Suicide & Crisis Lifeline is also available by call or text, 24/7.
Not medical advice. Talk to your prescriber about your specific situation, medical history, and any symptoms you're experiencing.
